Skip to main content
. 2023 Apr 6;6:100200. doi: 10.1016/j.jtauto.2023.100200

Fig. 5.

Fig. 5

SARS-Cov2 anti-Spike cellular and humoral kinetics and responses are distinct between systemic lupus erythematosus (SLE) patients and Controls (Cont). A: Interferon gamma release assay (IGRA) response to the full length Spike recombinant protein according to the days from the last immunization. Short time post immune vaccine response (<50 days) and long-term decline of the immune response (≥50 days) are indicated. B: Follow-up levels of IGRA-Spike decline levels in 10 SLE patients and 6 Cont. C: Anti-Spike antibody response according to the days from the last immunization. D: Follow-up levels of anti-Spike antibody levels in SLE patients and Cont. P values and assay thresholds (dot line) are indicated.